- Home
- ELVN vs NVCR Comparison
ELVN vs NVCR Comparison
Compare ELVN & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ELVN | NVCR |
|---|---|---|
| Founded | 2016 | 2000 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.0B |
| IPO Year | 2020 | 2015 |
Fundamental Metrics
Financial Performance| Metric | ELVN | NVCR |
|---|---|---|
| Price | $55.44 | $15.06 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $43.40 | $28.08 |
| AVG Volume (30 Days) | 773.4K | ★ 1.8M |
| Earning Date | 05-11-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 3.17 | ★ 21.79 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $655,353,000.00 |
| Revenue This Year | N/A | $7.72 |
| Revenue Next Year | N/A | $6.74 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 8.28 |
| 52 Week Low | $14.79 | $9.82 |
| 52 Week High | $55.79 | $21.45 |
Technical Indicators
Market Signals| Indicator | ELVN | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 61.29 | 44.54 |
| Support Level | $25.63 | $14.85 |
| Resistance Level | N/A | $15.46 |
| Average True Range (ATR) | 2.46 | 1.12 |
| MACD | -0.22 | -0.16 |
| Stochastic Oscillator | 70.83 | 3.67 |
Price Performance
Historical ComparisonAbout ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.